$661 Million is the total value of Rhenman & Partners Asset Management AB's 96 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LH | Laboratory Corp of America Hgs | $10,015,000 | +14.0% | 81,000 | 0.0% | 1.51% | +8.1% | |
| ARIA | Ariad Pharmaceuticals Inc | $2,688,000 | +7.0% | 430,000 | 0.0% | 0.41% | +1.5% | |
| TSRO | Tesaro Inc | $2,663,000 | +30.5% | 50,899 | 0.0% | 0.40% | +24.0% | |
| XNCR | Xencor Inc | $2,651,000 | +19.6% | 181,303 | 0.0% | 0.40% | +13.6% | |
| TNDM | Tandem Diabetes Care Inc | $2,468,000 | +34.1% | 209,000 | 0.0% | 0.37% | +27.3% | |
| OMCL | Omnicell Inc | $2,300,000 | -0.0% | 74,000 | 0.0% | 0.35% | -5.2% | |
| TTPH | Tetraphase Pharmaceuticals Inc | $2,257,000 | +34.4% | 225,000 | 0.0% | 0.34% | +27.2% | |
| ESPR | Esperion Therapeutics Inc | $2,226,000 | -5.6% | 100,000 | 0.0% | 0.34% | -10.4% | |
| OREX | Orexigen Therapeutics Inc | $2,045,000 | -18.5% | 1,189,000 | 0.0% | 0.31% | -22.8% | |
| RGLS | Regulus Therapeutic Inc | $1,744,000 | +33.3% | 200,000 | 0.0% | 0.26% | +26.3% | |
| MRTX | Mirati Therapeutics Inc | $1,580,000 | -8.2% | 50,000 | 0.0% | 0.24% | -12.8% | |
| ARRY | Array BioPharma Inc | $1,561,000 | -7.5% | 370,000 | 0.0% | 0.24% | -12.3% | |
| AAVL | Avalanche Biotechnologies Inc | $1,466,000 | +15.5% | 154,006 | 0.0% | 0.22% | +9.9% | |
| DVAX | Dynavax Technologies Corp | $1,329,000 | -1.6% | 55,000 | 0.0% | 0.20% | -6.5% | |
| HOLX | Hologic Inc | $1,288,000 | -1.2% | 33,301 | 0.0% | 0.20% | -6.2% | |
| ANTH | Anthera Pharmaceuticals Inc | $1,160,000 | -23.8% | 250,000 | 0.0% | 0.18% | -28.0% | |
| BINDQ | BIND Therapeutics Inc | $306,000 | -48.7% | 133,535 | 0.0% | 0.05% | -51.6% | |
| THLD | Threshold Pharmaceuticals | $97,000 | -88.2% | 201,537 | 0.0% | 0.02% | -88.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-01-19
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.